Suggested remit: To appraise the clinical and cost effectiveness of eplontersen within its marketing authorisation for treating polyneuropathy caused by hereditary transthyretin amyloidosis.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6337

Provisional Schedule

Expected publication 14 August 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors AstraZeneca (eplontersen)
Others National Amyloidosis Centre, UCL
  Department of Health and Social Care
  NHS England
Patient carer groups Gene People
  UK ATTR Amyloidosis Patients Association
Professional groups Association of British Neurologists
  Royal College of Physicians
Comparator companies Alnylam (patisiran, vutrisiran)
  Akcea Therapeutics (inotersen) - not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
25 January 2024 Invitation to participate
21 November 2023 - 19 December 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6337
10 October 2023 In progress. DHSC referral received
29 August 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual